Note: outcomes attributed to adverse events.Changed to reflect adverse effect not product malfunction.Additional information from the rep indicated the following, ¿the patient was removed from bypass.The surgeon noticed the onxmc-25/33 valve leaflet was not working.The patient was opened up and the surgeon found that native tissue was impinging the prosthetic valve.The surgeon removed that valve and replaced it with the same size on-x valve.¿ the manufacturing records for the onxmc-25/33 sn (b)(4) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.The surgeon reported improper leaflet motion, reopened patient and observed leaflet obstruction due to native tissue impingement.The valve was explanted and replaced by a same size on-x valve.Restriction of leaflet motion due to native tissue impingement during surgery makes this a valve positioning issue that was identified by the surgeon and corrected upon replacement with another on-x valve of the same size.The instructions for use (ifu) specifically caution: "when seating the valve, ensure that no suture material or anatomic structures interfere with leaflet motion.The valve's rotation capability may be helpful in avoiding abnormal residual pathology that could interfere with leaflet motion." based on limited available information regarding "leaflet impingement" that, in-vivo would result in excessive leakage resulting in high regurgitation, there is insufficient information to determine a definitive cause of failure.This event does not identify additional hazards or modify the probability and severity of existing hazards.
|